CITY OF ST. JOSEPH HEALTH DEPARTMENT - COVID-19 Briefing September 9, 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CITY OF ST. JOSEPH HEALTH
DEPARTMENT
COVID-19 Briefing
September 9, 2021
TESTING Locations for COVID-19 in Non-Hospital Provider Locations
Buchanan County (By Appointment Only)
**The City of St. Joseph Health Department does not have specifics on the testing process at these locations. Please visit their websites or call for more details.** Mosaic Non-Hospital Providers
For established patients
Various Locations
Pharmacy Locations Urgent Care Locations Call the provider directly
(By Appointment or Walk-in) (Walk-in Service) NW Health Services
For established patients
CVS Mosaic Life Care Urgent Care 1515 St Joseph Ave, St. Joseph, MO 64505
For general public
3320 N Belt Hwy, St Joseph, MO 64506 2303 Village Dr, St. Joseph, MO 64506
1115 N Belt Hwy St. Joseph, MO 64506
930 N Belt Hwy, St Joseph, MO 64506 5001 Lake Ave, St. Joseph, MO 64504
(816) 271-7077
1301 S Belt Hwy, St Joseph, MO 64507
https://www.cvs.com/minuteclinic/covid-19-testing Peacock Pediatrics
Urgent Care Express For established patients
* Not a Medicaid Provider
3839 Frederick Ave. St. Joseph, MO 64506
Hy-Vee 4776 Verona Dr, St. Joseph, MO 64506
(816) 396-6026
(816) 396-9500
201 N Belt Hwy, St Joseph, MO 64506
https://www.hy-vee.com/my-pharmacy/services/covid-19-testing Downing Pediatrics
For established patients
Emergency Department 805 N 36th St Suite B, St. Joseph, MO 64506
(816) 396-8855
Walgreens (Walk-In Service)
4022 N Belt Hwy, Saint Joseph
3645 Frederick Ave, Saint Joseph 64506 Mosaic Life Care Emergency Department Advanced Dermatology & MediSearch
2620 S Belt Hwy, Saint Joseph 64503 For general public New and established patients; Walk-ins welcome
https://www.walgreens.com/findcare/covid19/testing 5325 Faraon St, St. Joseph, MO 64506 1427 Village Dr., St. Joseph, MO 64506
(816) 271-6000 (816) 364-1515
River City Laboratory
Walk-ins, new patients, results typically within 24 hours
For any corrections or additions, please call 816.236.1491 212 South Woodbine Road, St. Joseph, MO 64506
(816) 306-8108
VACCINATION Locations for COVID-19 Buchanan County
**The City of St. Joseph Health Department does not have specifics on the vaccination process at these locations. Please visit their websites or call for more details.**
City of St. Joseph Third Dose information MO VIP Vaccine Program
Health Department The FDA has amended the emergency use authorizations (EUAs) for Register to win $10,000!
Health Department Clinic Pfizer-BioNTech and the Moderna COVID-19 Vaccines to allow for
the use of an additional (third) dose in certain immunocompromised MO VIP is our state’s vaccine incentive program
904 S. 10th St, Suite B, St. Joseph, MO 64503 rewarding those who have chosen or will choose
individuals. A full list of conditions can be found on CDC’s website.
Monday – Friday, 8:00am – 11:00am and 1:00pm – 4:00pm https://www.cdc.gov/coronavirus/2019- to receive a COVID-19 vaccination. The Missouri
1st, 2nd, 3rd Doses - Moderna (if available) & Pfizer ncov/vaccines/recommendations/immuno.html Department of Health & Senior Services is partnering with
Pfizer vaccine for ages 12 and older the Missouri Lottery to draw 180 winners in 5 randomized
drawings who will win either $10,000 cash or $10,000
towards an education savings account. In total, the state
Pharmacies will award 900 individuals throughout the incentive
program. Learn More: https://covidvaccine.mo.gov/win/
CVS – 1st, 2nd, 3rd Doses Sam's Club - 1st, 2nd, 3rd Doses
Moderna - 5201 N Belt Hwy (Target) , St Joseph, MO 64506 Moderna - 5201 N Belt Hwy, St Joseph, MO 64506
Pfizer - 3320 N Belt Hwy, St Joseph, MO 64506 https://samsclub.com/covid Senior & Disabled Vaccine
Pfizer - 930 N Belt Hwy, St Joseph, MO 64506
Moderna - 1301 S Belt Hwy, St Joseph, MO 64507 Walgreens - 1st, 2nd, 3rd Doses Registration Assistance
https://www.cvs.com/coronavirus Pfizer - 4022 N Belt Hwy, Saint Joseph Seniors and those who are disabled in NWMO can
Pfizer - 3645 Frederick Ave, Saint Joseph 64506 seek assistance with vaccination registration,
Hy-Vee - 1st, 2nd, 3rd Doses Pfizer - 2620 S Belt Hwy, Saint Joseph 64503 coordinating round trip transportation for vaccination
Pfizer - 201 N Belt Hwy, St Joseph, MO 64506 https://www.walgreens.com/covid appointments, and setting up reminder calls!
https://www.hy-vee.com/my-pharmacy/covid-vaccine Contact Young at Heart Resources 1-888-844-5626 or
Walmart - 1st, 2nd, 3rd Doses at https://www.yahresources.org/
Rogers - 1st, 2nd, 3rd Doses Moderna & Pfizer - 4201 N Belt Hwy, St Joseph MO 64506
Moderna - N Belt Hwy, St Joseph, MO 64506 Moderna & Pfizer - 3022 S Belt Hwy St Joseph MO 64503
(816) 232-3348—Choose option 10 to register https://www.walmart.com/COVIDvaccine Mosaic Life Care
Patients that are established with a Mosaic Provider
(primary or specialty) can contact the provider
to schedule an appointment.
www.vaccines.gov ~ 1-800-232-0233 ~ TTY 1-888-720-7489 ~Disability Info/Access Line 1-888-677-1199
MO VIP COVID-19 VACCINE INCENTIVE PROGRAM
H T T P S : / / M O S TO P S C OV I D. C O M / W I N
Next Entry Deadline will be held September 22nd at 11:59pm
https://MOStopsCovid.com/win
MO VIP is our state's vaccine incentive program - rewarding those who have
chosen or will choose to receive a COVID-19 vaccination.
The Missouri Department of Health & Senior Services is partnering with the
Missouri Lottery to draw 180 winners in 5 randomized drawings who will win
either $10,000 cash or $10,000 towards an education savings account. In total,
the state will award 900 individuals throughout the incentive program.
Vaccination is the most effective and long-lasting tool for protection from this
infection. DHSS continues to encourage anyone age 12 and up to get vaccinated
against COVID-19.
COVID-19 VACCINE DASHBOARD
H T T P S : / / C O V I D VA C C I N E . M O . G O V / D ATA /
Number of Number of Total COVID-19 7-Day 7-Day Avg
County people who have Percent of population people who have Percent of population Doses Doses Doses
Name Initiated vaccination initiating vaccination completed vaccination completing vaccination Administered Administered Administered
Buchanan 21,069 24.1% 18,957 21.7% 38,389 437 62
COVID-19 IN BUCHANAN COUNTY
Confirmed Probable
Total Cases Hospitalizations Deaths Positivity Rate
Cases Cases
Total Count 14,367 10,063 4,304 18 212 8.17%
Change Since Last
+52 +40 +12 -8 0 N/A
Report
Confirmed case: The case meets the confirmed laboratory evidence, which is the detection of SARS-CoV-2 RNA in a clinical specimen using an approved detection test verified by a
certified testing laboratory.
Probable case: The case meets clinical criteria AND epidemiologic evidence (close contact with a confirmed or probable case; travel to or residence in an area with sustained, ongoing
community spread; or a member of a risk cohort as defined by public health authorities during an outbreak), with no confirmatory laboratory testing performed for COVID-19.
Positivity Rate - The 7-day positivity rate is based on PCR and Antigen testing rates for Buchanan County residents and will be updated once a week on Mondays.
Currently Hospitalized – Mosaic Daily Inpatient Update: COVID-19 patient count is minimal. If the Mosaic system has more than ten COVID-19 inpatients, their website will be
updated https://www.mymlc.com/General/coronavirus-covid-19/#DailyInpatientUpdate. Patients may not be Buchanan County residents.
BUCHANAN COUNTY
COVID-19 CASE DEMOGRAPHICS
Buchanan County Cases by Age Range
3000
2698 Buchanan County Cases by Gender
2500 2376
2087 2162 2080
2000
Male 6965
1521
1500 Female 7400
1000 723
551 Not Reported 2
500
0 1000 2000 3000 4000 5000 6000 7000 8000
0
Under 20 20-29 30-39 40-49 50-59 60-69 70-79 80+
BUCHANAN COUNTY
1 4 - D AY T R E N D
This is the number of new cases over the past 14 days.
The straight line shows the trend of new cases.
COVID-19
IN
MISSOURI
Missouri COVID-19 Dashboard will provide
COVID-19 data for state and county levels:
MO DHSS numbers have continued to
fluctuate as the state makes adjustments to
ensure COVID-19 cases are not counted
twice. This could occur if a person received
a positive antigen test followed up with a
confirmatory PCR test – initially some
people who fall into that category were
counted in both. In order to report
accurately, the state regularly reviews
positive tests and corrects the numbers. https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus/data/public-health/statewide.php
COVID-19 IN THE US AND WORLDWIDE
Worldwide as of September 9, 2021 United States as of September 9, 2021
Total Cases: 221,134,742 Total Cases: 40,523,954
Total Deaths: 4,574,089 Total Deaths: 652,480
Vaccine Doses Administered: 5,352,927,296 Vaccine Doses Administered: 377,622,065
* Source: World Health Organization https://covid19.who.int/
Note: You likely notice a difference in the case counts if you are following other organizations, such
as Johns Hopkins. The CDC updates case totals each day, reporting the cases numbers from the * Source: Center for Disease Control and Prevention https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days
previous day. Other sites use sources for real time counts.Monoclonal Antibody (mAb) Infusion Centers
Test positive for COVID or think you may have it?
Good news, there is a treatment available that may
reduce your risk of developing serious symptoms or
winding up in the hospital.
Depending on your age, health history, and how long
you’ve had symptoms of COVID-19, you may qualify for a
promising form of treatment for the disease. It’s called
monoclonal antibody (mAb) treatment. The key is
receiving this treatment within 10 days of contracting
COVID-19, so don’t wait to see how bad your case will be!
Monoclonal antibody (mAb) treatment may also be
administered to exposed close contacts who are at high
risk for developing severe COVID-19 illness.
Talk to your doctor about a referral.
There are two locations in our region currently offering mAb therapy:
• St. Joseph - Mosaic Life Care
• Cameron - Monoclonal Antibody Infusion Center, 214 McElwain Drive, Cameron, MO.
Call/text 816-312-8718 for details. You can also self-schedule to the Cameron location by
visiting their Patient Scheduling Form https://hipaa.jotform.com/212324982557057
To learn more about the monoclonal antibody infusion, visit https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patientsTesting, Testing: School Edition
A recent CDC study shows that the Delta variant can spread rapidly in
schools when unvaccinated teachers and staff have close, indoor
contact with unvaccinated children. While children have been less
affected by COVID-19 compared with adults, they can get sick with
COVID-19 and can spread it to others. A second CDC study shows that
rates of COVID-19-associated hospitalizations in children and
adolescents increased following the rise of the Delta variant in the
United States. Prevention strategies, including vaccination of school
staff and eligible students, universal indoor masking, staying home
when sick, and routine testing, are critical to schools reopening and
operating safely.
Note to readers: CDC’s COVID Data Tracker’s new Pediatric Data page shows
data and visualizations for children at the national, state, and community
level. Data and maps highlighting COVID-19 trends in children ages 0-17
years can help demonstrate the impact of the pandemic on this age group.
These data are important for understanding how children are affected by
COVID-19. Data can also inform the actions needed to prevent the spread of
COVID-19 among children and those who interact with them.
https://covid.cdc.gov/covid-data-tracker/#pediatric-data
Full report dated September 3, 2021: https://www.cdc.gov/coronavirus/2019 -ncov/covid-data/covidview/index.html
Starting Friday, February 12, 2021, COVIDView was replaced with the COVID Data Tracker Weekly Review. This new webpage and newsletter highlights key data from CDC’s COVID Data Tracker, narrative interpretations of
the data, and visualizations from the week. The new Weekly Review also summarizes important trends in the pandemic and brings together CDC data and reporting in a centralized location. It represents the extensive data
that CDC uses to track the pandemic on a daily basis and incorporates additional data sources in the future. Sign up to have the COVID Data Tracker Weekly Review delivered to your inbox every week.INFORMATION FOR HEALTH C ARE PROFESSIONALS
FDA NEWS RELEASE
Coronavirus (COVID-19) Update: August 31, 2021
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-august-31-2021
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
On August 27, the FDA made changes to the On August 30, FDA issued a letter to
authorized use of the monoclonal veterinarians and retailers asking for
antibodies bamlanivimab and etesevimab, assistance in sharing important safety
administered together. The Emergency Use information with consumers about the
Authorization now authorizes the use of dangerous misuse of animal ivermectin to
bamlanivimab and etesevimab, administered prevent or treat COVID-19 in people. As
together, only in states, territories, and U.S. noted in many recent news stories and in a
jurisdictions in which recent data shows the Health Alert from the U.S. Centers for Disease
combined frequency of variants resistant to Control and Prevention, poison control centers
bamlanivimab and etesevimab administered across the U.S. are seeing a sharp spike in
together is less than or equal to 5%. FDA has reports of people suffering adverse health
posted a list of states, territories, and U.S. effects after taking animal ivermectin. People
jurisdictions in which bamlanivimab and are purchasing various highly concentrated
etesevimab administered together are animal ivermectin drug formulations such as
currently authorized, and a list of states, “pour-on,” injectable, paste, and “drench” that
territories, and U.S. jurisdictions in which are intended for horses, cattle, and sheep, and
bamlanivimab and etesevimab administered taking these drugs has made some people very
together, are not currently authorized, and will sick. Even if animal drugs have the same active
periodically update both lists as new data and ingredient as an approved human drug, animal
information becomes available. drugs have not been evaluated for safety or
https://www.fda.gov/media/145801/download effectiveness in humans. Treating human
medical conditions with veterinary drugs can
https://www.fda.gov/media/151719/download be very dangerous.
CVM Letter to Veterinarians and Retailers: Help Stop Misuse of Animal Ivermectin to Prevent or Treat COVID-19 in Humans
https://www.fda.gov/animal-veterinary/animal-health-safety-and-coronavirus-disease-2019-covid-19/cvm-letter-veterinarians-and-retailers-help-stop-misuse-animal-ivermectin-prevent-or-treat-covid-19INFORMATION FOR HEALTH C ARE PROFESSIONALS
What’s New in NIH COVID-19 Treatment guidelines
https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/
Last updated September 3, 2021
Emergency Use Authorization of Casirivimab Plus Imdevimab as Post-Exposure Prophylaxis (PEP) for SARS-CoV-2 Infection
August 17, 2021 September 3, 2021
The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Casirivimab The COVID-19 Treatment Guidelines Panel’s Statement
Plus Imdevimab as Post-Exposure Prophylaxis (PEP) for SARS-CoV-2 Infection on the Prioritization of Anti-SARS-CoV-2 Monoclonal
Vaccination remains the most effective way to prevent SARS-CoV-2 infection. However, despite widespread Antibodies for the Treatment or Prevention of SARS-
availability of SARS-CoV-2 vaccines, a number of individuals are either not fully vaccinated or cannot mount CoV-2 Infection When There Are Logistical Constraints
adequate responses to the vaccine. Some of these people, if infected, are at high risk of progression to serious The Panel recommends using anti-SARS-CoV-2
COVID-19. On July 30, 2021, the FDA expanded the EUA indication for the anti-SARS-CoV-2 monoclonal antibodies monoclonal antibodies for the treatment of mild to moderate
casirivimab plus imdevimab to allow this combination to be used as PEP for selected individuals, as described below. COVID-19 and for post-exposure prophylaxis (PEP) of
The Panel recommends using casirivimab 600 mg plus imdevimab 600 mg administered as subcutaneous injections SARS-CoV-2 infection in individuals who are at high risk for
(AI) or an intravenous infusion (BIII) as PEP for people who are at high risk for progression to severe COVID-19 if progression to severe COVID-19, as outlined in the Food
infected with SARS-CoV-2 AND who have the following vaccination status AND exposure history: and Drug Administration (FDA) Emergency Use
Authorizations (EUAs). While there are currently no
Vaccination Status:
shortages of these monoclonal antibodies, logistical
Not fully vaccinated (defined as people who were never vaccinated or those who received the second vaccine dose in constraints (e.g., limited space, not enough staff who can
a two-dose series or a single-dose vaccineINFORMATION FOR HEALTH C ARE PROFESSIONALS
What’s New in NIH COVID-19 Treatment guidelines, cont’d
https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/
Last updated September 3, 2021
Therapeutic Management of Hospitalized Adults With COVID-19
https://www.covid19treatmentguidelines.nih.gov/management/clinical-
management/hospitalized-adults--therapeutic-management/
August 25, 2021
Therapeutic Management of Hospitalized Adults With COVID-19
This section has been updated to add new recommendations on when to use dexamethasone in
combination with either intravenous (IV) sarilumab or oral tofacitinib in certain hospitalized patients
with COVID-19.
The Panel recommends IV sarilumab as an alternative to IV tocilizumab only when IV tocilizumab
is not available or not feasible to use (BIIa).
The Panel recommends tofacitinib as an alternative to baricitinib only when baricitinib is not
available or not feasible to use (BIIa).
Clinical data and rationales supporting these recommendations are summarized in the updated
section.
Additions to this section also include changes to Figure 2 (including the footnotes) to reflect these
new recommendations, as well as a new table outlining the dosing regimens and duration of therapy
for the drugs recommended in Figure 2.INFORMATION FOR HEALTH C ARE PROFESSIONALS
Missouri Department of Health and Senior Services – Health Care Professionals
https://health.mo.gov/living/healthcondiseases/communicable/novel -coronavirus/professionals.php#collapseTwo
Centers for Disease Control and Prevention (CDC) - Healthcare Workers: Information on COVID-19
https://www.cdc .gov/coronavirus/2019 -nCoV/hcp/index.html
National Institutes of Health - Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
https://www.covid19treatmentguidelines.nih.gov/
U.S. Food & Drug Administration – COVID-19
https://www.fda.gov/emergency -preparedness-and-response/counter terrorism -and-emerging-threats/coronavirus -disease-2019-covid-19
U.S. Department of Health and Human Services – COVID-19
https://www.hhs.gov/coronavirus/index.html
SOURCES OF INFORMATION
Missouri Department of Health and Senior Services
https://health.mo.gov/living/healthcondiseases/communicable/novel -coronavirus/
Center for Disease Control and Prevention
h t t p s : / /w w w.c dc. g ov/ co r on avi ru s/ 20 19 - nco v/ in de x.h t m l
World Health Organization
https://covid19.who.int/You can also read
